Lai Kai Pharmaceutical Technology
PublicLai Kai Pharmaceutical Technology is now publicly traded
The data on this page reflects Lai Kai Pharmaceutical Technology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 29, 2023
Last Round
Private Placement
Sep 24, 2025
Total Funding Raised
$344.31M
Company Overview
Laekna Therapeutics (HKG: 02105) is a biotechnology company focused on developing innovative therapies for cancer treatment through a robust R&D infrastructure and multiple clinical trials.
Sector
Biotech
AI Layer
Non-AI
Keywords
Lai Kai Pharmaceutical Technology Comparables
Compare Lai Kai Pharmaceutical Technology with similar companies based on industry and business-model similarity.
No public comparables are available for Lai Kai Pharmaceutical Technology. Request access to learn about comparables coverage.
Request accessLai Kai Pharmaceutical Technology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Sep 24, 2025 | ||||
| IPO | Jun 29, 2023 | ||||
| Series D | May 18, 2022 | ||||
| Series C | Oct 1, 2020 | ||||
| Series B | Apr 2, 2019 | ||||
Series A | Jun 4, 2018 |
Lai Kai Pharmaceutical Technology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed Asia | Series B, Series A |
| Yanchuang Capital | Series D |
| CS Capital | IPO, Series C, Series D |
| Ningbo Yaoshang Yanchuang Chenkai Venture Capital Partnership (Limited Partnership) | IPO |
| SDIC Innovation Investment Management | IPO |
| OrbiMed | Series B, Series A, IPO |
| Infinity Capital | Series D |
Lai Kai Pharmaceutical Technology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access